Irbesartan E Idroclorotiazide Pensa (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan E Idroclorotiazide Pensa, is an angiotensin II receptor blocker and thiazide diuretic combination presented as an oral tablet for systemic use. It treats hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Irbesartan E Idroclorotiazide Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Hypertension in diabetes: helps control blood pressure while mitigating renal complications associated with diabetes. - Hypertension with chronic kidney disease: provides blood‑pressure control in patients with reduced renal function, supporting kidney protection.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Increased urination or frequency of bathroom visits. - Mild headache. - Electrolyte disturbances such as low potassium. - Fatigue or general weakness. - Mild gastrointestinal upset, including nausea.

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, difficulty breathing). - Significant drops in blood pressure leading to fainting. - Acute kidney injury or worsening renal function. - Hyperkalemia (high potassium levels) in susceptible patients. - Liver enzyme elevations indicating hepatic stress. - Blood disorders such as leukopenia or thrombocytopenia.

Before starting therapy, consider the following precautions: - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Breastfeeding: use only if the benefit outweighs potential risk to the infant. - Renal impairment: dose adjustment may be required; monitor kidney function. - Electrolyte monitoring: regularly check sodium, potassium, and chloride levels. - Concomitant use with other antihypertensives: may cause additive blood‑pressure lowering effects. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels may cause toxicity. - ACE inhibitors or other ARBs: additive renal effects and hyperkalemia. - NSAIDs: may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment. - Corticosteroids: may increase potassium loss. - Anticoagulants: thiazide‑induced changes in plasma volume can affect INR. - Digoxin: electrolyte shifts may predispose to digoxin toxicity.